USA Fibroid Centers

What USA Fibroid Centers does

USA Fibroid Centers is a privately held, for-profit healthcare services company that operates a national network of 60+ outpatient centers dedicated exclusively to Uterine Fibroid Embolization (UFE), an FDA-approved, minimally invasive interventional radiology procedure that blocks blood flow to fibroids, causing them to shrink while preserving the uterus. The company was founded in 2009 by Dr. Yan Katsnelson, MD, and operates as Medical Management of Chicago, LLC under the USA Clinics Group umbrella alongside sister brands covering veins, vascular disease, hemorrhoids, prostate, oncology, longevity, and pain. The corporate office is at 304 Wainwright Drive, Northbrook, IL, and locations span New York, New Jersey, Pennsylvania, Georgia, Virginia, Washington DC, Illinois, Indiana, Florida, Texas, Connecticut, Maryland, and Washington.

The company delivers UFE using catheter-delivered embolic agents performed by specialized interventional radiologists in outpatient settings, with procedure times of approximately 30-45 minutes, no hospital stay, and a 1-2 week return-to-work versus 6-8 weeks for hysterectomy. Adjacent offerings include Uterine Artery Embolization (UAE) for adenomyosis, advanced ultrasound-based fibroid mapping, telemedicine consultations, real-time insurance verification, and a digital symptom quiz. Access channels combine online self-scheduling, phone intake, physician referrals, telemedicine, and in-network acceptance with Medicare, Medicaid, and major commercial payers.

Revenue is generated on a fee-for-service professional services model, with payment primarily from insurance reimbursements supplemented by out-of-pocket payments and flexible payment plans. The go-to-market is direct-to-consumer with heavy investment in consumer education (200+ blog articles, SEO, social media, webinars) and celebrity-driven awareness (Cynthia Bailey, Toya Johnson, Filbert the Fibroid mascot). The target segments are women with symptomatic fibroids, women seeking uterus-preserving treatment, women approaching menopause, African-American women (up to 80% prevalence by age 50), and Medicaid recipients. Clinical evidence cited includes a 95% efficacy rate per NIH, 90%+ patient satisfaction, an 86% quality-of-life improvement in the company's own JAMA Network Open study covering 271,000+ patient encounters, and 3,500+ Google reviews averaging 4.9 stars.

Name

USA Fibroid Centers

Legal name

Medical Management of Chicago, LLC

Website

https://usafibroidcenters.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

USA Fibroid Centers is a private, for-profit network of 60+ outpatient centers in the US that performs Uterine Fibroid Embolization (UFE), a minimally invasive, non-surgical procedure for women with symptomatic fibroids, paid via insurance reimbursement and direct patient fees.

Ownership category

akta.pro rank

Product category

Outpatient Fibroid Treatment Services

NAICS

Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Obstetrics & Gynecology (OB/GYN) Clinics (HLAFAJAA)

Keywords

• Minimally invasive fibroid treatment
• Uterine fibroid embolization
• Outpatient women's health
• Interventional radiology centers
• Non-surgical fibroid care

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. UFE Procedure Services: Fee-for-service revenue from performing Uterine Fibroid Embolization procedures at outpatient centers. Revenue derived from insurance reimbursements (Medicare, Medicaid, private insurers) and patient payments. Most major insurance plans accepted.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

USA Fibroid Centers operates a national network of 60+ outpatient centers performing Uterine Fibroid Embolization (UFE) and Uterine Artery Embolization (UAE), FDA-approved, minimally invasive, image-guided interventional radiology procedures that block blood supply to fibroids to shrink them while preserving the uterus. Services are delivered through outpatient facilities with online self-scheduling, real-time insurance verification, and telemedicine consultations for initial assessments, and are supported by an in-house clinical evidence base and patient education program.

Product overview

USA Fibroid Centers operates as a healthcare services provider offering a network of over 40 outpatient fibroid treatment centers specializing in Uterine Fibroid Embolization (UFE). The company's primary product is UFE, a non-surgical, minimally invasive procedure that treats fibroids by blocking their blood supply while preserving the uterus. The service portfolio includes related offerings such as Uterine Artery Embolization (UAE) for adenomyosis, a fibroid symptom checker tool, telemedicine consultations, insurance verification services, and supplementary medical services at select locations. The company positions UFE as an alternative to surgical options like hysterectomy and myomectomy.

Differentiator

Problem solved

Functional benefit

Products and services

• Uterine Fibroid Embolization (UFE) Non-surgical, FDA-approved, minimally invasive outpatient procedure that treats uterine fibroids by blocking their blood supply, causing them to shrink and symptoms to improve; preserves the uterus, takes roughly 30-45 minutes to 1 hour, requires no general anesthesia, involves no abdominal scarring, and allows return to work in 1-2 weeks. Targeted at adult women with symptomatic fibroids seeking an alternative to hysterectomy or myomectomy.
• Uterine Artery Embolization (UAE) for Adenomyosis Image-guided embolization procedure for adenomyosis using the same catheter-based embolic technique as UFE, performed by interventional radiologists at USA Fibroid Centers' outpatient facilities. Targeted at women diagnosed with adenomyosis who want a non-surgical, uterus-preserving treatment option.
• Telemedicine / Virtual Consultation Remote consultation service that lets prospective and existing patients meet USA Fibroid Centers' fibroid specialists virtually for initial evaluations and follow-up care, expanding access in areas without a nearby center. Targeted at adult women seeking convenient pre-procedure assessments.
• Real-time Insurance Verification & Billing Support Stand-alone insurance-coverage service integrated into online scheduling that confirms UFE/UAE coverage in real time, including Medicare, Medicaid, and major private insurers, with patient-support staff handling billing questions. Targeted at prospective patients needing clarity on coverage and out-of-pocket costs before committing to treatment.
• Other Outpatient Medical Services Supplementary outpatient services offered at select USA Fibroid Centers locations, including vein treatment, hemorrhoid treatment, knee pain treatment, PAD treatment, CT scans, and prostate treatment, which leverage the same outpatient clinical infrastructure. Targeted at patients of the affiliated locations who can receive additional specialty care during the same visit footprint.

Quantifiable outcome

• 86% improvement in patient quality of life reported in their landmark outpatient UFE study
• +6 more outcomes

Named customers13 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• USA Clinics GroupcoreOthersParent corporate organization that includes USA Fibroid Centers along with sister companies: USA Vein Centers, USA Vascular Centers, USA Hemorrhoid Centers, USA Prostate Centers, USA Oncology Centers, USA Longevity Centers, and USA Pain Centers. All operating under shared corporate infrastructure at 304 Wainwright Drive, Northbrook, IL 60062.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• USA Hemorrhoid Centers: Sister USA Clinics Group brand operating outpatient specialty clinics with the same DTC acquisition playbook and shared back-office infrastructure as USA Fibroid Centers.
• USA Vein Clinics: Sister company under the same USA Clinics Group parent; operates a national network of outpatient specialty clinics using a near-identical DTC, multi-site, fee-for-service model — providing the closest like-for-like operational benchmark.
• USA Prostate Centers: Another sister brand under USA Clinics Group applying the same focused outpatient clinic model to a different single-procedure specialty; highly comparable on operating model, footprint strategy, and parent-level resourcing.
• USA Vascular Centers: Sister USA Clinics Group brand focused on vascular interventions; shares the parent's real estate, marketing, and clinical infrastructure and validates the multi-brand specialty clinic model.

Regional players

• Inova Health System Fibroid Center: Hospital-based fibroid program in the Mid-Atlantic that offers both UFE and surgical options; represents the integrated delivery system competitor model in a key USA Fibroid Centers geography.

Broad incumbents

• Atrium Health Women's Care: Large health system with dedicated fibroid and OB/GYN service lines offering surgical and minimally invasive treatments; competes for the same patient pool within its regional footprint.
• Hologic (Acessa Health): Owns the Acessa laparoscopic radiofrequency ablation system, an alternative minimally invasive fibroid treatment; a major women's health incumbent whose commercial muscle could accelerate alternatives to UFE.
• Center for Vein Restoration: Largest independent U.S. network of vein treatment clinics with a similar multi-site outpatient specialty model and DTC marketing approach; useful benchmark for clinic-level unit economics and national rollouts.
• Vein Clinics of America: Established multi-site outpatient specialty clinic network in a parallel specialty (vein treatment); comparable on patient acquisition, payer contracting, and clinic-level operating model.

Emerging players

• Gynesonics: Developer of the Sonata system, a transcervical fibroid ablation procedure that competes head-to-head with UFE; relevant as a competing modality and potential future threat to UFE share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/USAFibroid
• LinkedInlinkedin.com/company/usa-fibroid-centers

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USA Fibroid Centers